Aurinia Pharmaceuticals Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, new issues for the quarter ending 2020-12-31 was -$12.27M.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, new issues for the quarter ending 2020-09-30 was $200.00M.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, new issues for fiscal 2021 was $196.74M, a 4.80% increase from fiscal 2020.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, new issues for fiscal 2020 was $187.73M, a 15.86% decline from fiscal 2019.
- Aurinia Pharmaceuticals Inc. stock issued during period, value, new issues for fiscal 2019 was $223.12M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2021-12-31 | $196.74M 10-K · filed 2024-02-15 | |
| 2020-12-31 | -$12.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $187.73M 10-K · filed 2023-02-28 |
| 2020-09-30 | $200.00M 10-Q · filed 2021-11-03 | |
| 2019-12-31 | $223.12M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |